News & Updates
Filter by Specialty:
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
23 Mar 2024
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
22 Mar 2024
ESK-001 makes good STRIDEs for plaque psoriasis
In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.
